Thymosin Beta-4 (Tβ4)
43-Amino Acid Regenerative Peptide | Tissue Repair & Healing
Community Research
Join others researching Thymosin Beta-4 — share findings, ask questions, and learn from real experiences
Naturally occurring 43-amino acid peptide crucial for tissue repair, wound healing, and cellular regeneration. Promotes angiogenesis, reduces inflammation, and supports cell migration and differentiation.
Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects including angiogenesis, cell migration, and differentiation.
Molecular Data
?SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGESAc
Position 1
Serine
Position 2
Aspartic Acid
Position 3
Lysine
Position 4
Proline
Position 5
Aspartic Acid
Position 6
Methionine
Position 7
Alanine
Position 8
Glutamic Acid
Position 9
Isoleucine
Position 10
Glutamic Acid
Position 11
Lysine
Position 12
Phenylalanine
Position 13
Aspartic Acid
Position 14
Lysine
Position 15
Serine
Position 16
Lysine
Position 17
Leucine
Position 18
Lysine
Position 19
Lysine
Position 20
Threonine
Position 21
Glutamic Acid
Position 22
Threonine
Position 23
Glutamine
Position 24
Glutamic Acid
Position 25
Lysine
Position 26
Asparagine
Position 27
Proline
Position 28
Leucine
Position 29
Proline
Position 30
Serine
Position 31
Lysine
Position 32
Glutamic Acid
Position 33
Threonine
Position 34
Isoleucine
Position 35
Glutamic Acid
Position 36
Glutamine
Position 37
Glutamic Acid
Position 38
Lysine
Position 39
Glutamine
Position 40
Alanine
Position 41
Glycine
Position 42
Glutamic Acid
Position 43
Serine
Position 44
Research Indications
Clinical trials show 67% complete healing versus 25% placebo in pressure ulcers.
Enhanced tissue regeneration and reduced healing time in surgical wounds.
Accelerated recovery in muscle, tendon, and ligament injuries.
Phase 2b trials show 43% reduction in infarct size when given within 6 hours.
Improved neurological outcomes and functional recovery in animal models.
Dosing Protocols
Systemic regenerative effects with proven clinical efficacy and optimal bioavailability.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acute Wound Healing | 1.6mg | Daily | SubQ |
| Cardiac Protection | 42mg | Single dose | IV bolus within 6 hours of MI |
| Chronic Tissue Repair | 6mg | Twice weekly | SubQ |
| Neurological Recovery | 30mg | Three times over 72 hours | IV infusion |
| General Regeneration | 2-5mg | Daily or every other day | SubQ |
Reconstitution Instructions
- Thymosin β4 lyophilized powder (sterile vial)
- Bacteriostatic water for injection (BWFI)
- Sterile syringes and needles
- Alcohol swabs and sterile gauze
- 1 Allow lyophilized powder to reach room temperature before reconstitution
- 2 Add bacteriostatic water slowly to vial wall, avoiding direct powder contact
- 3 Gently swirl (do not shake vigorously) until completely dissolved
- 4 Inspect solution for clarity—should be clear and colorless
- 5 Store reconstituted solution at 2-8°C and use within 14 days
- 6 Use proper aseptic technique and rotate injection sites
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Mild injection site reactions
- Local inflammation at injection sites
Stop Signs - Discontinue if:
- Severe injection site reactions or persistent inflammation
- Signs of systemic allergic reaction (rash, breathing difficulty)
- Unexpected cardiovascular symptoms during treatment
- Any signs of infection at injection sites
Contraindications
- Active chemotherapy treatment
- Severe systemic allergies to peptides
Quality Checklist
Good Signs
- Clear, colorless solution when reconstituted
- Proper sterile packaging with intact seals
- Certificate of analysis showing >98% purity
- Appropriate molecular weight confirmed via HPLC/MS
Warning Signs
- Room temperature storage claims—legitimate product requires refrigeration after reconstitution
Bad Signs
- Cloudy or discolored solution indicating degradation
- Crystallization after reconstitution suggesting improper storage
References
- Phase II Dry Eye Clinical Trial(2015)
72 subjects showing significant positive effects on ocular discomfort and corneal staining with excellent safety profile.
- Phase I Human Safety Study: Intravenous Thymosin β4(2010)
First-in-human study establishing safety and pharmacokinetics in healthy volunteers with no dose-limiting toxicity.
- Cardiac Protection Pilot Study: Thymosin β4 in STEMI Patients(2016)
First human study in heart attack patients demonstrating potential clinical benefits in repairing damaged tissue.
- Neurotrophic Keratopathy Compassionate Use Trial(2010)
Complete clearing of persistent corneal defects in most subjects using topical formulation.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.